Quirk Gerald E 4
4 · Syros Pharmaceuticals, Inc. · Filed Oct 20, 2023
Insider Transaction Report
Form 4
Quirk Gerald E
Chief Legal Officer
Transactions
- Tax Payment
Common Stock
2023-10-19$2.10/sh−6,897$14,484→ 24,303 total - Exercise/Conversion
Restricted Stock Units
2023-10-11−22,500→ 22,500 total→ Common Stock (22,500 underlying) - Exercise/Conversion
Common Stock
2023-10-11+22,500→ 31,200 total
Footnotes (4)
- [F1]Represents shares of common stock received upon vesting of a restricted stock unit award.
- [F2]Represents shares used to cover tax withholding on a restricted stock unit release.
- [F3]Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
- [F4]Represents a restricted stock unit award granted on October 11, 2022. These restricted stock units vested as to one half (50%) of the shares on October 11, 2023, and are scheduled to vest as to one half (50%) of the shares on March 31, 2024.